- 1、本文档共6页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
门诊对照莫西
International Journal of Antimicrobial Agents 29 (2007) 56–61
Efficacy and safety of 3-day azithromycin versus 5-day
moxifloxacin for the treatment of acute bacterial
exacerbations of chronic bronchitis
Marcus Zervos a,∗, Fernando J. Martinezb , Guy W. Amsden c ,
Constance D. Rothermel d , Glenda Treadway d
a Henry Ford Hospital, Detroit, MI, USA
b University of Michigan Medical Center, Ann Arbor, MI, USA
c The Bassett Healthcare Research Institute’s Clinical Research Division and Department of Pharmaceutical Care Services,
Bassett Healthcare, Cooperstown, NY, USA
d Pfizer Inc., New York, NY, USA
Received 10 July 2006; accepted 9 August 2006
Abstract
Antibiotic therapy is of clinical benefit in certain patients with acute exacerbations of chronic bronchitis (AECB). In this randomised,
investigator-blinded, multicentre trial, azithromycin (500 mg once a day (qd) for 3 days) was compared with moxifloxacin (400 mg qd for
5 days) for the treatment of outpatients with AECB (forced expiratory volume in 1 s (FEV1) 35%). Of 342 patients randomised to either
treatment, 169 received azithromycin and 173 received moxifloxacin. The mean age in the azithromycin and moxifloxacin groups was 56.4
years and 55.5 years, respectively. In the intent-to-treat analysis, clinical success rates for azithromycin and moxifloxacin were comparable at
Days 10–12 (90% versus 90%, respectively) and Days 22–26 (81% versus 82%, respectively). Among patients who were culture-positive at
baseline for Strept
文档评论(0)